{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"30.8","value":"0"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"21.9","value":"4.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"Percentage of participants with Grade III/IV acute GVHD. Severe GVHD is defined as Grade III/IV acute GVHD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device\n\nAra-C: day-8 through day-5\n\n3 g/m2 q 12 hours\n\nCyclophosphamide: day-7 and day-6\n\n45 mg/kg\n\nCampath-1H: day-3 through day-1\n\nDosing for children:\n\n5 - 15kg : 3mg IV in 30ml NS\n\n15.1 - 30kg : 5mg IV in 50ml NS\n\n\\>30 kg : 10mg IV in 100ml NS\n\nAdults will receive 10mg IV in 100ml NS\n\nTotal Body Irradiation: day-4 through day-1\n\n175 cGy x 2 at 24 cGy/min\n\nStem Cell Infusion: Stem cells are infused on day 0","id":"OG000","title":"CLINIMACS Device"},{"description":"Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device\n\nAra-C: day-8 through day-5\n\n3 g/m2 q 12 hours\n\nCyclophosphamide: day-7 and day-6\n\n45 mg/kg\n\nCampath-1H: day-3 through day-1\n\nDosing for children:\n\n5 - 15kg : 3mg IV in 30ml NS\n\n15.1 - 30kg : 5mg IV in 50ml NS\n\n\\>30 kg : 10mg IV in 100ml NS\n\nAdults will receive 10mg IV in 100ml NS\n\nTotal Body Irradiation: day-4 through day-1\n\n175 cGy x 2 at 24 cGy/min\n\nStem Cell Infusion: Stem cells are infused on day 0","id":"OG001","title":"ISOLEX Device"}],"paramType":"NUMBER","populationDescription":"A participant is evaluable for acute GVHD if the participant engrafted and either completed 100 days observation after transplant or experienced acute GVHD. Of the 46 participants at baseline, eight participants in CLINIMACS and five in ISOLEX were not evaluable for acute GVHD and were not included in this analysis.","reportingStatus":"POSTED","timeFrame":"100 Days","title":"Severe GVHD Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}